Table 4.
Risk factors including fibrosis-4 index for mortality in patients with COVID-19 receiving respiratory support
| Variable | Univariate | Multivariate analysis | |
| P value* | P value* | HR (95% CI) | |
| Male (yes/no) | 0.143 | ||
| Comorbidities (yes/no) | |||
| Hypertension | 0.392 | ||
| Diabetes | 0.001 | 0.009 | 1.917 (1.181 to 3.111) |
| Chronic obstructive pulmonary disease | 0.087 | ||
| Chronic kidney disease | 0.841 | ||
| Chronic liver disease | 0.226 | ||
| ACE inhibitor/ARB use (yes/no) | 0.871 | ||
| Lymphocyte count, /µL | |||
| <1010 | 1 (ref) | ||
| ≥1010 | 0.012 | 0.012 | 0.480 (0.271 to 0.852) |
| C reactive protein, mg/L | 0.584 | ||
| Total bilirubin, mg/dL | 0.831 | ||
| Alkaline phosphatase, U/L | 0.725 | ||
| Gamma glutamyl transferase, U/L | 0.263 | ||
| Serum albumin, g/dL | 0.773 | ||
| Prothrombin time, INR | 0.444 | ||
| Estimated glomerular filtration rate, mL/min/1.73 m2 | 0.002 | ||
| SIRS on admission (yes/no) | <0.001 | 0.032 | 1.714 (1.048 to 2.802) |
| Fibrosis-4 index | |||
| <4.95 | 1 (ref) | ||
| ≥4.95 | <0.001 | <0.001 | 2.784 (1.691 to 4.585) |
*Calculated by Cox proportional hazards regression test.
ARB, angiotensin II receptor blocker; INR, international normalised ratio; SIRS, systemic inflammatory response syndrome.